FIELD: chemistry.
SUBSTANCE: invention relates to a sodium salt of formula I 
compound in the solid amorphous form. The sodium salt of formula (I) compound is obtained by (a) the preparation of a mixture of the formula I compound in a non-aqueous solvent and a water solution of sodium hydroxide; and (b) drying by spraying of the mixture (a) in a spray-drying device. The stage (a) includes mixing the sodium hydroxide solution with the said solvent and further addition of the formula I compound. The solvent is represented by halogen-containing hydrocarbon. The invention also relates to a pharmaceutical composition, possessing HCV inhibiting properties, including sodium salt of the formula I compound in the amorphous form, and a pharmaceutically acceptable carrier.
EFFECT: sodium salt of the formula (I) compound for application as HCV inhibitor and medication for HCV treatment.
10 cl, 7 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING HEPATITIS C | 2013 |
|
RU2665365C2 |
| AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYLINDOL-1-YL)-ACETIC ACID | 2012 |
|
RU2616000C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | 2006 |
|
RU2440822C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| COMPOSITION OF THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | 2014 |
|
RU2661399C1 |
| HEMI-SULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS | 2018 |
|
RU2787616C2 |
| DERIVATIVES OF (4-METHYLSULPHONYLAMINOPHENYL)-QUINOLINE, USEFUL IN TREATMENT OF HEPATITIS C | 2011 |
|
RU2572835C2 |
| MACROCYCLIC HEPATITIS C INHIBITORS | 2006 |
|
RU2436787C2 |
| PHENYLETHYNYL DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | 2010 |
|
RU2538507C2 |
| CYCLOSPORIN DERIVATIVES, SUBSTITUTED WITH 3-ETHER AND 3-THIOETHER FOR TREATING AND PREVENTING INFECTIOUS HEPATITIS C | 2005 |
|
RU2399628C2 |
